Prevalent mechanisms of resistance among common enterobacterial isolates in Greek hospitals

Klebsiella and extended spectrum beta-lactamases

During the past 14 years a rapid, world-wide increase in prevalence of Klebsiella pneumoniae resistant to late generation cephalosporins has occurred. A growing number of newly identified plasmid encoded beta-lactam hydrolyzing enzymes has broadened the spectrum of primitive beta-lactamases allowing inactivation of a wide variety of beta-lactam agents. The extrachromosomal genes which code for these enzymes often exist with genes expressing resistance to several other classes of antibacterial agents, potentially arming Klebsiella pneumoniae with resistance to all therapeutically available antibiotics. More focused surveillance studies and individualized strategies within institutions are necessary to reduce this insidious trend.

Molecular epidemiology and antibiotic resistance of Enterobacter spp. from three distinct populations in Grampian, UK

The distribution of Enterobacter spp. within the population of Aberdeen Royal Infirmary was compared with the outpatient population with regard to molecular epidemiology and antibiotic resistance. Enterobacter spp. from 60 patients and one environmental site were characterised as ITU, non ITU and outpatients' isolates. Thirty-five percent were blood culture isolates. Cefotaxime resistant strains in the hospital were frequent. Cefotaxime (64%) sensitive isolates were inducible for hyperproduction of Bush group 1 beta-lactamase. Isolates were further investigated by PFGE. Isolates (27%) were clonally related and typed in four clusters. Consecutive isolates were studied in selected patients showing minor genomic changes. One environmental isolate from a deep sink at ITU was related to a patient's isolate.

Extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a neonatal intensive care unit in the high-prevalence area of Athens, Greece

Extended-spectrum beta-lactamase-producing Klebsiella pneumoniae (EPKP) strains are frequently implicated in outbreaks in neonatal intensive care units (NICUs). During the period from 1997 to 1998, 21 infections and 23 colonizations with EPKP were recorded in the NICU of a children's hospital in Athens, Greece. Seventeen of the infected and 12 of the colonized neonates had been referred from other hospitals. The remaining infections and colonizations occurred during the current hospitalization. Pulsed-field gel electrophoresis typing showed that the latter cases were due to an outbreak strain that persisted in the unit, while the repeated introduction of EPKP carriers was mostly due to clonal outbreaks in two maternity hospitals.

Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors

Bacteria belonging to the genus Klebsiella frequently cause human nosocomial infections. In particular, the medically most important Klebsiella species, Klebsiella pneumoniae, accounts for a significant proportion of hospital-acquired urinary tract infections, pneumonia, septicemias, and soft tissue infections. The principal pathogenic reservoirs for transmission of Klebsiella are the gastrointestinal tract and the hands of hospital personnel. Because of their ability to spread rapidly in the hospital environment, these bacteria tend to cause nosocomial outbreaks. Hospital outbreaks of multidrug-resistant Klebsiella spp., especially those in neonatal wards, are often caused by new types of strains, the so-called extended-spectrum-beta-lactamase (ESBL) producers. The incidence of ESBL-producing strains among clinical Klebsiella isolates has been steadily increasing over the past years. The resulting limitations on the therapeutic options demand new measures for the management of Klebsiella hospital infections. While the different typing methods are useful epidemiological tools for infection control, recent findings about Klebsiella virulence factors have provided new insights into the pathogenic strategies of these bacteria. Klebsiella pathogenicity factors such as capsules or lipopolysaccharides are presently considered to be promising candidates for vaccination efforts that may serve as immunological infection control measures.